Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Food and Drug Administration Safety and Innovation Act (FDASIA)

Food and Drug Administration Safety and Innovation Act (FDASIA)

                        FDASIA Title VII Drug Supply Chain Provisions
          FDASIA Title VII Overview
          FDASIA Section 907: Inclusion of Demographic Subgroups in Clinical Trials Home
          Regulatory Information
          Laws Enforced by FDA
          Selected Amendments to the FD&C Act
          Food and Drug Administration Safety and Innovation Act (FDASIA)
          FDASIA Section 907: Inclusion of Demographic Subgroups in Clinical TrialsFood and Drug Administration Safety and Innovation Act (FDASIA) FDASIA Section 907: Inclusion of Demographic Subgroups in Clinical Trials
  
  	
    Share
    Post
    Linkedin

    Email
    PrintFDA’s**Action Plan for FDASIA Section 907The FDASIA Sec. 907 Action Plan recommends that medical product applications submitted for marketing approval improve their demographic subgroup data’s completeness, quality, and availability.Commissioner Robert Califf, M.D., Blog: 2016: The Year of Clinical Trials DiversityFDASIA 907 Public Meeting: Progress on Enhancing the Collection, Analysis and Availability of Demographic Subgroup Data on February 29, 2016Clinical Trials: Assessing Safety and Efficacy for a Diverse Population - Meeting co-sponsored by FDA and Johns Hopkins for Excellence in Regulatory Science InnovationAction Plan to Enhance the Collection and Availability of Demographic Subgroup Data (PDF- 1013 KB)Questions & Answers**Presentation Slides**Office of Minority Health FDASIA 907 Action Plan UpdateOffice of Women's Health FDASIA 907 Action Plan UpdateProgress in Data Quality, Participation, and Transparency at FDAEnhancing the Collection and Availability of Demographic Subgroup DataCBER Update: Enhancing the Collection and Availability of Demographic Subgroup DataBackgroundMedical products are safer and more effective for everyone when clinical research includes diverse populations.Sec. 907 of the Food and Drug Administration Safety and Innovation Act (FDASIA) directed FDA to investigate how well demographic subgroups (sex, age, race and ethnicity) in applications for medical products – drugs, biologics and devices, submitted to the agency for marketing approval:1) Are included in clinical trials; and2) If subgroup-specific safety and effectiveness data are available.Sec. 907 also required the FDA to provide Congress with an action plan detailing “recommendations for improving the completeness and quality of analyses of data on demographic subgroups in summaries of product safety and effectiveness data and in labeling; on the inclusion of such data, or the lack of availability of such data, in labeling; and on improving the public availability of such data to patients, health care professionals, and researchers” and to indicate the center(s) tasked with each recommendation.  Congress directed the Agency to issue the action plan one year following the publication of the Sec. 907 report.To fulfill these directives, FDA systematically evaluated sponsor applications, FDA reviews, and product labeling, and examined 72 medical products submitted to FDA for marketing approval in 2011. The agency published a final report on the investigation in August 2013. FDA accepted public comments to the report for 90 days and also held many other small group meetings with stakeholders. On April 1, 2014, FDA held a public hearing seeking input from stakeholders  - including clinical researchers, industry, academia, health care providers and patient advocates on issues and challenges associated with the collection, analysis and availability of demographic subgroup data to inform the development of an action plan that is pragmatic and public health focused.  Additionally, the original docket was reopened until May 16, 2014.Action Plan Priority AreasThe Sec. 907 Action Plan thoughtfully considers public feedback, congress’s requirements, and the initial report’s findings. The plan outlines the agency’s current policies and practices, and presents 27 action items focused on three priorities:1. **Quality**: to improve the completeness and quality of demographic subgroup data;2. **Participation**: to identify barriers to subgroup enrollment in clinical trials and employ strategies to encourage greater participation;3. **Transparency**: to improve the public availability of demographic subgroup data.The FDA’s *Action Plan to Enhance the Collection and Availability of Demographic Subgroup Data*reflects the Agency’s commitment to encourage the inclusion and greater representation of a diverse patient population in biomedical research leading to the development of medical products.  Increasing representation is a multi-faceted challenge that will require collaboration of our federal partners, industry, health care professionals, patient advocacy groups and community-based organizations.  We will continue to work with our stakeholders and continue the dialogue on this important issue.  As we move forward with implementation of the Sec. 907 Action Plan, we will provide updates and progress on the action items to this webpage.If you would like to provide feedback to the Agency, please email us at FDASIA907@fda.hhs.govRelated ResourcesFederal Register Notice- Request for Information on Specific Areas of Public Health Concern Related to Racial/Ethnic Demographic Subgroups for Additional ResearchFDASIA Section 907 ReportPublic Hearing TranscriptFull text of the FDASIA statutePublic Hearing Remarks by Margaret Hamburg, MDView Slides for FDA Webinar on Inclusion of Minorities in Clinical Trials (FDASIA 907)Brochure: Become a Research Volunteer (Printer-Friendly)View Slides for FDA Webinar: Get to Know ClinicalTrials.govFDA Voice BlogsRecent Progress on Demographic Information and Clinical TrialsClinical Trials: Enhancing Data Quality, Encouraging Participation and Improving TransparencyFDA Wants Your Perspective on Clinical Trial Demographic Data

                                                                                  Content current as of:
      03/28/2018Food and Drug Administration Safety and Innovation Act (FDASIA)

          
                        FDASIA Title VII Drug Supply Chain Provisions
          FDASIA Title VII Overview
          FDASIA Section 907: Inclusion of Demographic Subgroups in Clinical Trials
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop